Naratriptan hydrochloride

Overview

Naratriptan (GR-85548A) hydrochloride is a selective 5-HT1B/1D receptor agonist. Naratriptan hydrochloride is peripherally active and has good oral bioavailability, inducing cranial artery vasoconstriction by activating 5-HT1B/1D receptors (EC 50 =0.11 μM for dog basilar artery). Naratriptan hydrochloride also inhibits trigeminal nerve-mediated dural neurogenic plasma extravasation and reduces sterile inflammation. Naratriptan hydrochloride is mainly used in the research of acute migraine, targeting cranial vascular and neuroinflammatory mechanisms.

Application

Products | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Depression | Products > Disease Areas > Cardiovascular Disease | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Obesity | Products > Disease Areas > Infection | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Neuronal Signaling | Products > Research Areas > Neurological Disease | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > 5-HT Receptor

Product Information

• Catalog No.: HY-B0197A
• CAS No.: 143388-64-1
• Molecular Formula: C17H26ClN3O2S
• Molecular Weight: 371.93
• Purity: 99.69%
• Storage: -20°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Solubility: 6.67 mg/mL (17.93 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
• Availability: In-stock

Source

Original product source